1 Small-Cap Stock That Could Soar in 2023
Last year was an important one for Bluebird Bio (NASDAQ: BLUE) as the biotech company earned two key regulatory approvals in the U.S. Despite these wins, the market has hardly rewarded the gene-editing specialist; its shares are down 39% in the past year, and Bluebird's market capitalization is currently just $323 million.
This biotech could have massive upside if its master plan for the rest of the year and beyond comes to fruition. But should investors consider adding shares of Bluebird to their portfolios today? Let's find out.
Bluebird focuses on developing medicines for rare diseases. The company's newly approved therapies are Zynteglo, which targets transfusion-dependent beta-thalassemia (TDT, a rare blood disorder), and Skysona, a medicine for cerebral adrenoleukodystrophy (CALD, a progressive, pediatric, and fatal neurodegenerative disease).
Source Fool.com
